Abstract
6531 Background: Prognosis has improved for BL/BLL, particularly with short, intensive, multi-agent chemotherapy. Outcome of 26 non-HIV BL/BLL patients (pts) treated with hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone) showed CR rate of 81% with induction mortality 19% owing to systemic fungal infections in pts aged 60 years (yrs) and older [Thomas et al, JCO 17:2461, 1999]. Older age was an adverse feature predicting relapse with shorter 3-yr survival compared with younger pts (17% vs 77%). Methods: The program was modified with the induction course given in laminar air flow rooms for older pts. Rituximab was added for high CD20 expression. From November 1999 to April 2004, 31 pts with newly diagnosed BL (n=15) or BLL (n=16) were treated (HIV-positive pts reported separately). The median age was 46 yrs (range, 17–77) with 29% aged 60 yrs or older. Ann Arbor stage was III/IV in 80% (7% had CNS involvement). Rituximab 375 mg/m2 was given days 1 and 11 of courses 1 & 3 wi...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
